ReviewDiseases (Basel, Switzerland)2026
First Reported Use of Recombinant Parathyroid Hormone in Kenny-Caffey Syndrome Type 2: A Case Report and Literature Review.
Maja Djordjevic Milosevic, Anita Skakic, Marina Andjelkovic, Angelica Maria Delgado-Vega, Håkan Thonberg, Kristel Klaassen, Jovana Komazec, Bozica Kecman, Nikola Jocic, Erik Björck and 2 more
Abstract readReview
In one paragraphReview in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Maja Djordjevic MilosevicInstitute for Mother and Child Healthcare of Serbia "Dr Vukan Cupic", 11070 Belgrade, Serbia.ORCID 0009-0001-7427-9222 Anita SkakicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.ORCID 0000-0002-1213-4458 Marina AndjelkovicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Angelica Maria Delgado-VegaDepartment of Clinical Genetics and Genomics, Karolinska University Hospital, 17164 Stockholm, Sweden.ORCID 0000-0002-9865-0591 Håkan ThonbergDepartment of Clinical Genetics and Genomics, Karolinska University Hospital, 17164 Stockholm, Sweden.
Kristel KlaassenInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.ORCID 0000-0002-3077-6091 Jovana KomazecInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.ORCID 0000-0003-0369-9729 Bozica KecmanInstitute for Mother and Child Healthcare of Serbia "Dr Vukan Cupic", 11070 Belgrade, Serbia.
Nikola JocicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Erik BjörckDepartment of Clinical Genetics and Genomics, Karolinska University Hospital, 17164 Stockholm, Sweden.
Anna LindstrandDepartment of Clinical Genetics and Genomics, Karolinska University Hospital, 17164 Stockholm, Sweden.ORCID 0000-0003-0806-5602 Maja StojiljkovicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Funding
European Commission (HORIZON-WIDERA-2023-ACCESS-02) 101160079
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
FAM111A genehypoparathyroidismKenny–Caffey syndrome type 2parathyroid hormone therapytreatment
Identifiers
PMID41891992
PMCPMC13025059
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390